Literature DB >> 22593093

An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury.

Jeffrey L Woodhead1, Brett A Howell, Yuching Yang, Alison H Harrill, Harvey J Clewell, Melvin E Andersen, Scott Q Siler, Paul B Watkins.   

Abstract

N-acetylcysteine (NAC) is the treatment of choice for acetaminophen poisoning; standard 72-h oral or 21-h intravenous protocols are most frequently used. There is controversy regarding which protocol is optimal and whether the full treatment course is always necessary. It would be challenging to address these questions in a clinical trial. We used DILIsym, a mechanistic simulation of drug-induced liver injury, to investigate optimal NAC treatment after a single acetaminophen overdose for an average patient and a sample population (n = 957). For patients presenting within 24 h of ingestion, we found that the oral NAC protocol preserves more hepatocytes than the 21-h intravenous protocol. In various modeled scenarios, we found that the 21-h NAC infusion is often too short, whereas the full 72-h oral course is often unnecessary. We found that there is generally a good correlation between the time taken to reach peak serum alanine aminotransferase (ALT) and the time taken to clear N-acetyl-p-benzoquinone imine (NAPQI) from the liver. We also found that the most frequently used treatment nomograms underestimate the risk for patients presenting within 8 h of overdose ingestion. V(max) for acetaminophen bioactivation to NAPQI was the most important variable in the model in determining interpatient differences in susceptibility. In conclusion, DILIsym predicts that the oral NAC treatment protocol, or an intravenous protocol with identical dosing, is superior to the 21-h intravenous protocol and ALT is the optimal available biomarker for discontinuation of the therapy. The modeling also suggests that modification of the current treatment nomograms should be considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593093     DOI: 10.1124/jpet.112.192930

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Authors:  Kyunghee Yang; Cen Guo; Jeffrey L Woodhead; Robert L St Claire; Paul B Watkins; Scott Q Siler; Brett A Howell; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

Review 2.  An Update on Treatment of Drug-Induced Liver Injury.

Authors:  Christin Giordano; John Rivas; Xaralambos Zervos
Journal:  J Clin Transl Hepatol       Date:  2014-06-15

3.  Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.

Authors:  K Yang; J L Woodhead; P B Watkins; B A Howell; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2014-07-28       Impact factor: 6.875

4.  A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial.

Authors:  B A Howell; S Q Siler; L K M Shoda; Y Yang; J L Woodhead; P B Watkins
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-05

5.  Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.

Authors:  Jeffrey L Woodhead; Kyunghee Yang; Scott Q Siler; Paul B Watkins; Kim L R Brouwer; Hugh A Barton; Brett A Howell
Journal:  Front Pharmacol       Date:  2014-11-07       Impact factor: 5.810

6.  Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.

Authors:  Brian J Schmidt; Fergal P Casey; Thomas Paterson; Jason R Chan
Journal:  BMC Bioinformatics       Date:  2013-07-10       Impact factor: 3.169

7.  Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches.

Authors:  Sudin Bhattacharya; Lisl K M Shoda; Qiang Zhang; Courtney G Woods; Brett A Howell; Scott Q Siler; Jeffrey L Woodhead; Yuching Yang; Patrick McMullen; Paul B Watkins; Melvin E Andersen
Journal:  Front Physiol       Date:  2012-12-14       Impact factor: 4.566

8.  New therapeutic approach: diphenyl diselenide reduces mitochondrial dysfunction in acetaminophen-induced acute liver failure.

Authors:  Nélson R Carvalho; Edovando F da Rosa; Michele H da Silva; Cintia C Tassi; Cristiane L Dalla Corte; Sara Carbajo-Pescador; Jose L Mauriz; Javier González-Gallego; Félix A Soares
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

9.  Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI.

Authors:  J L Woodhead; K Yang; K L R Brouwer; S Q Siler; S H Stahl; J L Ambroso; D Baker; P B Watkins; B A Howell
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-07-09

10.  Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.

Authors:  D M Longo; Y Yang; P B Watkins; B A Howell; S Q Siler
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.